Ocular allergy remains a significant burden to the population while the treatment for the severe, chronic forms of allergic conjunctivitis remains largely limited to non-specific immunosuppressants. Eosinophils are central to the pathophysiology and sustaining the immunologic response found in the chronic forms of ocular allergy such as vernal keratoconjunctivitis and atopic keratoconjunctivitis. Several mediators of eosinophil recruitment, chemotaxis, adhesion, activation, and survival have been identified that offer potential therapeutic targets for ocular allergy. Based on preclinical and clinical data available in both ocular and non-ocular allergy studies, these emerging therapies warrant further investigation in reducing the severity of disease in patients with chronic ocular allergy.

眼部过敏仍然是人群的重大负担，而严重、慢性形式的过敏性结膜炎的治疗仍然主要限于非特异性免疫抑制剂。嗜酸性粒细胞是病理生理学的核心，并维持在慢性眼部过敏（例如春季角膜结膜炎和特应性角膜结膜炎。已经确定了嗜酸性粒细胞募集、趋化性、粘附、激活和存活的几种介质，它们为眼部过敏提供了潜在的治疗靶点。根据眼部和非眼部过敏研究中可用的临床前和临床数据，这些新兴疗法值得进一步研究，以降低慢性眼部过敏患者的疾病严重程度。